ICML 2025

Dr Claire Roddie

Claire Roddie is a Consultant Haematologist and Honorary Senior Lecturer in Haematology at University College London with a particular interest in Chimeric Antigen Receptor (CAR) T-cells for Cancer. She completed a PhD in Cellular Immunotherapy at UCL in the laboratory of Professor Karl Peggs and subsequently undertook a Clinician Scientist post in Dr Martin Pule

Prof Jason Westin

Professor Westin works at the University of Texas as the leader of the research team exploring DLBCL at the MD Anderson Cancer Center in the Department of Lymphoma and Myeloma. Prof Westin obtained his Microbiology degree and his Medicine degree from the University of Florida, USA. He then went on to study Clinical and Translational Sciences at the University of Texas Graduate School of Biomedical Sciences. His post-graduate training included his clinical residency at The University of North Carolina, his clinical fellowship in haematology/oncology at MD Anderson Cancer Center where he was also chief fellow, and his research fellowship in Advanced Scholar-Lymphoma at the MD Anderson Cancer Center.

Prof Westin is an active member of many institutional committees and acts or has acted as a board member or chair of several boards and societies. Prof Westin has also been the recipient of many honours and awards from many prestigious societies and foundations. Prof Westin also has a substantial number of publications across many respected journals.

He is an active member of the American Association for Physician Leadership, American Association for Cancer Research, Association for Patient-Oriented Research, American Society of Haematology, and the American Society of Clinical Oncology.

Prof Marie Jos+

Marie Jos+

Prof Michael Dickinson

Michael Dickinson is the Lead of the Aggressive Lymphoma group within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. Michael specialises as a principal investigator in Phase 1/2 clinical trials of new anticancer drugs with a focus on Aggressive Lymphomas and novel immunotherapies, improving outcomes of diffuse large B-cell lymphoma and mantle cell lymphoma. His investigator-initiated studies have focused on the role of epigenetic modifiers in haematological malignancies, new CAR T combinations, and advancing the role of bispecific antibodies in lymphoma. Michael's clinical research includes industry and investigator-led trials in lymphoma, Phase 1 trials of drugs and novel cellular therapies for lymphoma. He has over 120 publications including in NEJM, JCO, Blood, and Nature Medicine.